InsiderTrades.com logo
Kyle Piskel net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Kyle Piskel Biography and Net Worth

CFO of Adaptive Biotechnologies

Kyle Piskel is the Chief Financial Officer at Adaptive Biotechnologies, a commercial-stage biotech company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease. Since joining Adaptive in 2015, Kyle has held various positions of ascending responsibility within finance and accounting, including Corporate Controller and Principal Accounting Officer. Prior to joining Adaptive, Kyle worked at Expedia Group and Ernst & Young, LLP.  Kyle is a Certified Public Accountant. 

What is Kyle Piskel's net worth?

The estimated net worth of Kyle Piskel is at least $2.02 million as of March 5th, 2025. Mr. Piskel owns 269,010 shares of Adaptive Biotechnologies stock worth more than $2,022,955 as of April 2nd. This net worth estimate does not reflect any other investments that Mr. Piskel may own. Additionally, Mr. Piskel receives an annual salary of $375,900.00 as CFO at Adaptive Biotechnologies. Learn More about Kyle Piskel's net worth.

How old is Kyle Piskel?

Mr. Piskel is currently 40 years old. There are 7 older executives and no younger executives at Adaptive Biotechnologies. The oldest executive at Adaptive Biotechnologies is Ms. Stacy L. Taylor, Senior VP, General Counsel & Corporate Secretary, who is 64 years old. Learn More on Kyle Piskel's age.

What is Kyle Piskel's salary?

As the CFO of Adaptive Biotechnologies Co., Mr. Piskel earns $375,900.00 per year. There are 4 executives that earn more than Mr. Piskel. The highest earning executive at Adaptive Biotechnologies is Mr. Chad M. Robins M.B.A., Co-Founder, CEO & Chairman, who commands a salary of $1,000,000.00 per year. Learn More on Kyle Piskel's salary.

How do I contact Kyle Piskel?

The corporate mailing address for Mr. Piskel and other Adaptive Biotechnologies executives is 1551 EASTLAKE AVENUE EAST SUITE 200, SEATTLE WA, 98102. Adaptive Biotechnologies can also be reached via phone at (206) 659-0067 and via email at investors@adaptivebiotech.com. Learn More on Kyle Piskel's contact information.

Has Kyle Piskel been buying or selling shares of Adaptive Biotechnologies?

Kyle Piskel has not been actively trading shares of Adaptive Biotechnologies over the course of the past ninety days. Most recently, Kyle Piskel sold 10,320 shares of the business's stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $6.98, for a transaction totalling $72,033.60. Following the completion of the sale, the chief financial officer now directly owns 269,010 shares of the company's stock, valued at $1,877,689.80. Learn More on Kyle Piskel's trading history.

Who are Adaptive Biotechnologies' active insiders?

Adaptive Biotechnologies' insider roster includes R. Adams (COO), Lance Baldo (Insider), Sharon Benzeno (Insider), Chad Cohen (CFO), Egon Durban (Director), David Goel (Director), Michelle Griffin (Director), Robert Hershberg (Director), Francis Lo (Insider), Peter Neupert (Director), Jyoti Palaniappan (SVP), Kyle Piskel (CFO), Chad Robins (CEO), Chad Robins (CEO), Harlan Robins (Insider), Julie Rubinstein (President), and Stacy Taylor (SVP). Learn More on Adaptive Biotechnologies' active insiders.

Are insiders buying or selling shares of Adaptive Biotechnologies?

During the last twelve months, insiders at the sold shares 12 times. They sold a total of 757,849 shares worth more than $6,041,858.67. The most recent insider tranaction occured on March, 24th when insider Harlan S Robins sold 1,698 shares worth more than $15,282.00. Insiders at Adaptive Biotechnologies own 6.2% of the company. Learn More about insider trades at Adaptive Biotechnologies.

Information on this page was last updated on 3/24/2025.

Kyle Piskel Insider Trading History at Adaptive Biotechnologies

See Full Table

Kyle Piskel Buying and Selling Activity at Adaptive Biotechnologies

This chart shows Kyle Piskel's buying and selling at Adaptive Biotechnologies by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$50k$0$50kTotal Insider BuyingTotal Insider Selling

Adaptive Biotechnologies Company Overview

Adaptive Biotechnologies logo
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.
Read More

Today's Range

Now: $7.52
Low: $7.13
High: $7.63

50 Day Range

MA: $7.91
Low: $6.67
High: $8.66

2 Week Range

Now: $7.52
Low: $2.28
High: $9.01

Volume

2,403,291 shs

Average Volume

1,478,476 shs

Market Capitalization

$1.12 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.53